Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 16/20 | 0.76 |
| ▸ | S1PR2 | O95136 | 13/20 | 0.44 |
| ▸ | S1PR3 | Q99500 | 13/20 | 0.44 |
| ▸ | LPAR2 | Q9HBW0 | 8/20 | 0.44 |
| ▸ | S1PR4 | O95977 | 5/20 | 0.41 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.39 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.38 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.37 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16468703 | 1.00 | S1PR1 (0.76) | S1PR1S1PR2S1PR3LPAR2S1PR4 | |
| SCHEMBL16468923 | 1.00 | S1PR1 (0.76) | S1PR1S1PR2S1PR3LPAR2S1PR4 | |
| SCHEMBL16506098 | 0.92 | S1PR1 (0.79) | S1PR1S1PR2S1PR3LPAR2S1PR4 | |
| SCHEMBL16506355 | 0.91 | S1PR1 (0.80) | S1PR1S1PR2S1PR3LPAR2S1PR4 | |
| SCHEMBL15193661 | 0.89 | S1PR1 (0.77) | S1PR1S1PR2S1PR3LPAR2ADRB2 | |
| SCHEMBL15193769 | 0.88 | S1PR1 (0.78) | S1PR1S1PR2S1PR3LPAR2ADRB2 | |
| SCHEMBL15192395 | 0.87 | S1PR1 (1.00) | S1PR1S1PR2S1PR3LPAR2S1PR4 | |
| SCHEMBL16469145 | 0.87 | S1PR1 (0.58) | S1PR1S1PR2S1PR3LPAR2S1PR4 | |
| SCHEMBL15193832 | 0.86 | S1PR1 (0.75) | S1PR1S1PR2S1PR3LPAR2ADRB2 | |
| SCHEMBL16468792 | 0.85 | S1PR1 (0.73) | S1PR1CHRM2ADRB2ADRB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150051176-A1 | ARYL DERIVATIVES AS SPHINGOSINE-1 PHOSPHATE RECEPTORS MODULATORS | ALLERGAN, INC. | 2015-02-19 | — | — | US | claimed |
| WO-2015023837-A1 | ARYL DERIVATIVES AS SPHINGOSINE-1 PHOSPHATE RECEPTORS MODULATORS | ALLERGAN, INC. (US) | 2015-02-19 | — | — | WO | claimed |
| US-20150051176-A1 | ARYL DERIVATIVES AS SPHINGOSINE-1 PHOSPHATE RECEPTORS MODULATORS | ALLERGAN, INC. | 2015-02-19 | — | — | US | disclosed |
| US-20150051176-A1 | ARYL DERIVATIVES AS SPHINGOSINE-1 PHOSPHATE RECEPTORS MODULATORS | ALLERGAN, INC. | 2015-02-19 | — | — | US | disclosed |
| US-20150051176-A1 | ARYL DERIVATIVES AS SPHINGOSINE-1 PHOSPHATE RECEPTORS MODULATORS | ALLERGAN, INC. | 2015-02-19 | — | — | US | disclosed |
| WO-2015023837-A1 | ARYL DERIVATIVES AS SPHINGOSINE-1 PHOSPHATE RECEPTORS MODULATORS | ALLERGAN, INC. (US) | 2015-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150051176-A1 | ARYL DERIVATIVES AS SPHINGOSINE-1 PHOSPHATE RECEPTORS MODULATORS | S1PR1, S1PR3, S1PR2 | S1PR1 1/4885S1PR2 3/4885S1PR3 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.